Supernus Pharmaceuticals (SUPN) EBIT (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of EBIT data on file, last reported at -$3.9 million in Q4 2025.

• EBIT for Q4 2025 came in at -$3.9 million, down 118.39% year-over-year; the trailing twelve-month figure through Dec 2025 was -$62.3 million (down 176.27% YoY), and the FY2025 annual result was -$62.3 million, down 176.27% from the prior year.
• EBIT climbed to -$3.9 million in Q4 2025 per SUPN's latest filing, from -$60.2 million in the prior quarter.
• Over five years, EBIT peaked at $40.8 million in Q3 2024 and troughed at -$60.2 million in Q3 2025.
• A 5-year average of $7.3 million and a median of $7.1 million in 2021 frame the typical range for EBIT.
• The sharpest annual moves came in 2023 and 2024: EBIT tumbled 255.01% in 2023, then jumped 2249.1% in 2024.
• A 5-year view of EBIT shows it stood at $6.1 million in 2021, then surged by 463.04% to $34.3 million in 2022, then sank by 102.9% to -$996000.0 in 2023, then jumped by 2249.1% to $21.4 million in 2024, then slumped by 118.39% to -$3.9 million in 2025.
• Business Quant data shows SUPN's EBIT at -$3.9 million in Q4 2025, -$60.2 million in Q3 2025, and $12.1 million in Q2 2025.